The Gaucher Disease Type I drugs in development market research report provides comprehensive information on the therapeutics under development for Gaucher Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gaucher Disease Type I. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gaucher Disease Type I and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Gaucher Disease Type I by ten companies/universities/institutes. The top development phase for Gaucher Disease Type I is phase ii with five drugs in that stage. The Gaucher Disease Type I pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Gaucher Disease Type I pipeline products market are: M6P Therapeutics, AceLink Therapeutics and Shanghai Lingyi Biotechnology.
The key targets in the Gaucher Disease Type I pipeline products market include Lysosomal Acid Glucosylceramidase, and Ceramide Glucosyltransferase.
The key mechanisms of action in the Gaucher Disease Type I pipeline product include Lysosomal Acid Glucosylceramidase Activator with five drugs in Phase II. The Gaucher Disease Type I pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Gaucher Disease Type I pipeline products market including Gene Therapy, and Recombinant Enzyme.
Gaucher Disease Type I overview
Type 1 Gaucher disease is a genetic condition that occurs when a fatty substance called glucocerebroside is not able to break down into glucose. It affects both children and adults. It is caused when not enough glucocerebrosidase (GBA) is made. GBA is an important enzyme that breaks down a fatty chemical called glucocerebroside. Because the body cannot break down this chemical, fat-filled Gaucher cells build up in areas like the spleen, liver and bone marrow. Major signs and symptoms include enlargement of the liver and spleen (hepatosplenomegaly), a low number of red blood cells (anemia), easy bruising caused by a decrease in blood platelets (thrombocytopenia), bone abnormalities such as bone pain and fractures, and joint conditions such as arthritis
For a complete picture of Gaucher Disease Type I’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
